Item 7.01 Regulation FD Disclosure.
Aquestive Therapeutics, Inc. (the "Company") is furnishing this Current Report
on Form 8-K in connection with the disclosure of information, in the form of an
investor presentation, to be given at meetings with institutional investors,
analysts and others (the "Investor Presentation"). This information may be
amended or updated at any time and from time to time through another Current
Report on Form 8-K, a later Company filing or other means. A copy of the
Company's Investor Presentation is attached hereto as Exhibit 99.1 to this
Current Report on Form 8-K and incorporated into this Item 7.01 by reference and
replaces in its entirety all prior investor presentations filed by the Company.
The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed
to be "filed" for purposes of, or otherwise subject to the liabilities of,
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), nor shall it be deemed to be incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in any such filing.
Item 8.01 Other Events.
On September 27, 2022, the Company issued a press release announcing its
positive EPIPHAST II Trial Data for AQST-109. A copy of the Company's press
release is attached hereto as Exhibit 99.2 and incorporated into this Item 8.01
by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit Description
Number
99.1 Investor Presentation dated September 2022.
99.2 Press Release dated September 27, 2022 announcing the Company's positive
EPIPHAST II Trial Data for AQST-109.
© Edgar Online, source Glimpses